Esomeprazole inhibits EGF-induced invasion and migration of gastric cancer cells
PeerJ · 2026
DOI: 10.7717/peerj.21675 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, 2026. Verfasst von Fangfang Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Zhengzhou Key Laboratory of Lipid Metabolism and Precision Diagnosis & Treatment in Oncology, Oncology Department, the Fifth Affiliated Hospital of Z…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Cell Movement, Epidermal Growth Factor, Esomeprazole. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Project of Henan Province, Key Scientific Research Project Plan of Henan Province.
Abstract (Originalsprache)
Background
Gastric cancer (GC) is one of the most prevalent and lethal malignancies worldwide, with invasion and metastasis being the key factors contributing to its poor prognosis and high mortality rates. Epidermal growth factor (EGF)-induced activation of EGFR and downstream AKT/mTOR signaling plays a central role in promoting cancer cell invasion and migration. While epidermal growth factor receptor (EGFR)-targeted therapies such as afatinib effectively inhibit these processes, the potential of esomeprazole (ESO) to modulate GC metastasis has not been fully elucidated. This study aims to investigate the inhibitory effect of ESO on EGF-induced invasion and migration of gastric cancer cells, and its relationship with the EGFR/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling pathway.
Methods
Cell viability, invasion, migration and protein expression were assessed using cell counting kit-8 (CCK-8) assay, Transwell assay, wound healing assay and western blot.
Results
ESO significantly reduced migration and invasion in GC cells, as well as the expression levels of N-cadherin, MMP2, MMP9, Vimentin, p-EGFR, p-AKT, and p-mTOR induced by EGF. The combination of ESO and afatinib (an irreversible EGFR inhibitor) led to a more pronounced reduction in cell viability, invasion, migration, and protein expression compared to either treatment alone.
Conclusions
ESO inhibits EGF-induced invasion and migration in GC cells potentially via the EGFR/AKT/mTOR pathway, offering a potential new strategy for GC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhengzhou Key Laboratory of Lipid Metabolism and Precision Diagnosis & Treatment in Oncology, Oncology Department, the Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou, Henan, China.
- Chongqing Emergency Medical Center, Chongqing, China.
- Henan Key Laboratory of Health Medicine and Liver Disease Prevention & Treatment, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Förderung
- Science and Technology Project of Henan Province
- Key Scientific Research Project Plan of Henan Province
Zitieren
APA
Huang, F., Du, J., Zhang, X., Tian, M., Lv, Q., Chu, X., Zhang, H., & Zhang, Z. (2026). Esomeprazole inhibits EGF-induced invasion and migration of gastric cancer cells. PeerJ. https://doi.org/10.7717/peerj.21675
Vancouver
Huang F, Du J, Zhang X, Tian M, Lv Q, Chu X, et al. Esomeprazole inhibits EGF-induced invasion and migration of gastric cancer cells. PeerJ. 2026. doi:10.7717/peerj.21675
BibTeX
@article{Huang2026,
author = {Huang, Fangfang and Du, Jinfeng and Zhang, Xuanruo and Tian, Mengru and Lv, Qiangqiang and Chu, Xiufeng and Zhang, Hongqiao and Zhang, Zisen},
title = {Esomeprazole inhibits EGF-induced invasion and migration of gastric cancer cells},
journal = {PeerJ},
year = {2026},
doi = {10.7717/peerj.21675}
}
EUVIMED